LGP2 Antibody (E-1): sc-373826
- LGP2 Antibody (E-1) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against amino acids 520-678 mapping at the C-terminus of LGP2 of human origin
- recommended for detection of LGP2 of human origin by WB, IP, IF and ELISA
- m-IgG2a BP-HRP is the preferred secondary detection reagent for LGP2 Antibody (E-1) for WB applications. This reagent is now offered in a bundle with LGP2 Antibody (E-1) (see ordering information below).
QUICK LINKS
SEE ALSO...
LGP2 Antibody (E-1) is a mouse monoclonal IgG2a antibody that detects LGP2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-LGP2 antibody (E-1) recognizes LGP2, a 678 amino acid protein that plays a crucial role in the regulation of the innate immune response against viral infections. Specifically, LGP2 functions as a negative regulator by binding to double-stranded RNA (dsRNA) produced during viral replication, which is essential for modulating the host′s immune response. By interacting with RIG-I, a key signaling protein in the defense against viruses like hepatitis C, LGP2 prevents the multimerization of RIG-I, thereby inhibiting its signaling pathway. This regulatory mechanism is vital for maintaining a balanced immune response, as excessive activation can lead to detrimental inflammation. Localized in the cytoplasm, LGP2 features one helicase ATP-binding domain and one helicase C-terminal domain, which are critical for its function in RNA unwinding and immune modulation. LGP2 monoclonal antibody (E-1) is an invaluable tool for researchers studying viral pathogenesis and the intricate dynamics of immune regulation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LGP2 Antibody (E-1) References:
- RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. | Widau, RC., et al. 2014. Proc Natl Acad Sci U S A. 111: E484-91. PMID: 24434553
- LGP2 synergy with MDA5 in RLR-mediated RNA recognition and antiviral signaling. | Bruns, AM. and Horvath, CM. 2015. Cytokine. 74: 198-206. PMID: 25794939
- RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate immune signaling. | Parisien, JP., et al. 2018. EMBO Rep. 19: PMID: 29661858
- LGP2 binds to PACT to regulate RIG-I- and MDA5-mediated antiviral responses. | Sanchez David, RY., et al. 2019. Sci Signal. 12: PMID: 31575732
- RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. | Zheng, W., et al. 2020. Cancer Res. 80: 5633-5641. PMID: 33087322
- Immune regulator LGP2 targets Ubc13/UBE2N to mediate widespread interference with K63 polyubiquitination and NF-κB activation. | Lenoir, JJ., et al. 2021. Cell Rep. 37: 110175. PMID: 34965427
- RNA sensing via the RIG-I-like receptor LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency. | Stok, JE., et al. 2022. EMBO J. 41: e109760. PMID: 35156720
- Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication. | Gillich, N., et al. 2023. J Hepatol. 78: 78-89. PMID: 36152765
- LGP2 directly interacts with flavivirus NS5 RNA-dependent RNA polymerase and downregulates its pre-elongation activities. | Tan, Z., et al. 2023. PLoS Pathog. 19: e1011620. PMID: 37656756
- Contrasting functions of ATP hydrolysis by MDA5 and LGP2 in viral RNA sensing. | Singh, R., et al. 2024. J Biol Chem. 300: 105711. PMID: 38309507
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LGP2 Antibody (E-1) | sc-373826 | 200 µg/ml | $322.00 | |||
LGP2 Antibody (E-1): m-IgG2a BP-HRP Bundle | sc-546050 | 200 µg Ab; 10 µg BP | $361.00 |